- Home
- PBT vs QURE Comparison
PBT vs QURE Comparison
Compare PBT & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBT | QURE |
|---|---|---|
| Founded | 1980 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | PBT | QURE |
|---|---|---|
| Price | $30.02 | $24.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | 201.0K | ★ 1.9M |
| Earning Date | 03-13-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.50% | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $126.12 |
| Revenue Next Year | N/A | $200.43 |
| P/E Ratio | $57.37 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.80 | $8.73 |
| 52 Week High | $31.85 | $71.50 |
Technical Indicators
Market Signals| Indicator | PBT | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 72.66 | 57.91 |
| Support Level | $16.88 | $21.16 |
| Resistance Level | N/A | $25.66 |
| Average True Range (ATR) | 1.90 | 2.23 |
| MACD | 0.58 | -0.20 |
| Stochastic Oscillator | 78.11 | 49.47 |
Price Performance
Historical ComparisonAbout PBT Permian Basin Royalty Trust
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole, and others across Texas. The company earns the majority of its revenue in the form of royalties received through its properties.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.